BPP’s continuous flow manufacturing technologies provide significant competitive advantages in the generics area including lower production costs, better quality control, support for marketing exclusivity by non-infringement of legacy patents, and more efficient production of generic versions of pharmaceuticals.

Our strategy is threefold:  1) build the finest, high quality relationships with global stake-holders to advance our Mission; 2) design, build and scale the smallest API manufacturing modulars in the world under the highest regulatory hurdle, the U.S. FDA, and gain a current Good Manufacturing Practices (“cGMP”) designation for our modulars; and 3) deploy our technologies globally through a distributive global network.